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a b s t r a c t
The case-control methodology is frequently used to evaluate vaccine effectiveness post-licensure. The
results of such studies provide important insight into the level of protection afforded by vaccines in a ‘real
world’ context, and are commonly used to guide vaccine policy decisions. However, the potential for bias
and confounding are important limitations to this method, and the results of a poorly conducted or incor-
rectly interpreted case-control study can mislead policies. In 2012, a group of experts met to review
recent experience with case-control studies evaluating vaccine effectiveness; we summarize the recom-
mendations of that group regarding best practices for data collection, analysis, and presentation of the
results of case-control vaccine effectiveness studies. Vaccination status is the primary exposure of inter-
est, but can be challenging to assess accurately and with minimal bias. Investigators should understand
factors associated with vaccination as well as the availability of documented vaccination status in the
study context; case-control studies may not be a valid method for evaluating vaccine effectiveness in set-
tings where many children lack a documented immunization history. To avoid bias, it is essential to use
the same methods and effort gathering vaccination data from cases and controls. Variables that may con-
found the association between illness and vaccination are also important to capture as completely as pos-
sible, and where relevant, adjust for in the analysis according to the analytic plan. In presenting results
from case-control vaccine effectiveness studies, investigators should describe enrollment among eligible
cases and controls as well as the proportion with no documented vaccine history. Emphasis should be
placed on confidence intervals, rather than point estimates, of vaccine effectiveness. Case-control studies
are a useful approach for evaluating vaccine effectiveness; however careful attention must be paid to the
collection, analysis and presentation of the data in order to best inform evidence-based vaccine policies.
Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
New vaccines are licensed based on the results of randomized
controlled trials demonstrating safety and efficacy. Yet even after
licensure, there are often questions about how well a vaccine pro-
tects against disease in a ‘‘real world” context because of differ-
ences in epidemiologic contexts, host factors affecting immune
response, vaccine implementation (e.g. varying dosing schedules),
and the potential for waning immunity over time [1]. The case-
control method is commonly used to estimate effectiveness after
a vaccine has been implemented in a public health system; recent
examples include evaluations of vaccines against Haemophilus
Influenzae type B (Hib) [2–13], Streptococcus pneumoniae [14–21],
influenza [22], rotavirus [23–36], and cholera [37–39]. The results
of case-control vaccine effectiveness studies can complement and
extend the data generated by clinical trials.
However the potential for bias and confounding are important
limitations to the case-control method [40,41]. In 2012, a group
of experts met to review recent experience with case-control stud-
ies evaluating the effectiveness of several vaccines; here we sum-
marize the recommendations of that group regarding best
practices for data collection, analysis and interpretation. (A sepa-
rate paper provides an overview of the case-control method for
evaluating vaccine effectiveness and reviews planning, design,
and the identification and enrollment of cases and controls.) While
case-control vaccine effectiveness studies have been carried out in
countries of all income levels, this review focuses on their imple-
mentation in resource-poor settings.
2. Assessment of vaccination status
Vaccination status is the primary exposure of interest for case-
control vaccine effectiveness studies, but it can be challenging to
assess it accurately [42]. Misclassification of vaccination status
can affect the VE estimates in various ways. Non-differential mis-
classification of vaccination status (i.e. cases and controls have
similar risks of misclassification) will bias the effectiveness esti-
mate towards the null [41]. Differential misclassification (i.e. vac-
cine classification errors have different probabilities in cases and
controls) can bias the effectiveness estimate towards or away from
the null, or even result in a negative VE, giving the false impression
that vaccinated are at greater risk of the target disease than unvac-
cinated [41]. The same strategies to obtain vaccination history
should be used for both cases and controls. Equal, intense effort
must be made to obtain vaccination histories from all cases and
controls [40,43], and those efforts should be clearly documented
and reported.
Preferred sources of vaccination data are family-held vaccine
records, clinic records, immunization registry data, or other writ-
ten documentation of vaccines received and the dates on which
they were administered. Doses not recorded on these documents
are assumed to have not been received; although this assumption
may be incorrect if recordkeeping is poor. Parent reporting of rou-
tine infant immunizations received, without written verification,
may be unreliable [44]. However, if parents report receipt of no
vaccines of any type or receipt of only birth doses, such a history
may be valid even in the absence of written confirmation since
unvaccinated children rarely will have family-held records and
generally parents are unlikely to state that the child is unvacci-
nated when in fact he or she did receive vaccines. Because exclud-
ing unvaccinated children will lead to bias, children with a parental
report of having received no routine vaccines beyond birth doses
should be included and considered to have received no doses of
the vaccine of interest. All eligible cases and controls should be
enrolled regardless of whether a documented vaccination history
is available at the time of enrollment. Although those lacking a
confirmed vaccination history (other than unvaccinated children)
will be excluded from primary analyses because of missing data,
the proportion of enrolled children for whom vaccination history
could not be obtained should be described in the results, and sen-
sitivity analyses used to assess the impact of missing data on the
effectiveness estimates (see Section 5).
Investigators should endeavor to understand factors associated
with vaccination card availability and retention in the study set-
ting, and whether those factors may also be linked to risk of disease
or likelihood of vaccination [45]. In preparation for the study,
efforts can be made to improve availability of cards and/or the
quality and completeness of data in the clinic records. If vaccine
histories are unavailable for a sizeable proportion of children in
the area (e.g.5–10%), then efforts should be made to assess differ-
ences between children with and without documented histories. If
important differences exist with regards with risk factors for dis-
ease, then a case-control study in that context is likely to yield
biased effectiveness estimates. Case-control studies may not be a
valid method for evaluating VE in settings where more than a small
fraction of children lack a documented immunization history.
Abstracting vaccination data from family-held cards or clinic
records is not always straightforward and can be a source of bias.
Copies of the vaccination data source (e.g. digital photo, photo-
copies, or scanned images of the card or record) are extremely use-
ful for controlling data quality. Copies can be used for double-
abstraction (e.g. by two independent observers), which may
improve the quality of data, particularly in settings where interpre-
tation of information in the record may be challenging, for exam-
ple, where parental-held records have no dedicated space for a
new vaccine or for vaccines administered during campaigns.
Copies potentially allow for blinding with regard to case or control
status for the person abstracting the vaccination data [40]. Vaccine
3304 J.R. Verani et al. / Vaccine 35 (2017) 3303–3308
lot numbers, if recorded, can aid in determining which vaccines
were received. Dates of all relevant vaccine doses, including the
vaccine of interest and other vaccines given on the same or similar
schedules, should be carefully recorded.
3. Other variables and unmeasured confounding factors
In addition to vaccination status, data should be gathered on
other variables that may confound the association between vacci-
nation and the disease of interest [46,47]. Known or hypothesized
confounders should be identified before study initiation, accurately
and thoroughly captured during data collection, and adjusted for in
the analysis if they confound the association between vaccination
and illness. As with all observational studies, some degree of
unmeasured confounding often occurs in case-control studies
and has the potential to substantially alter the measured VE [48].
Unmeasured confounding may result from failure to collect data
on a known confounder, insufficient or inadequate data collection
for a known confounder, or lack of data on an unrecognized or
unknown confounder.
A few strategies to quantify unmeasured confounders have
been suggested. The first has been called a ‘‘bias-indicator”
[37,39,49] or ‘‘sham outcome” [50] study. This is performed con-
currently with a case-control study of vaccine effectiveness, where
the effectiveness of the studied vaccine is measured against
another disease which is not expected to be prevented by the vac-
cine [37,39,49]. As the vaccine should confer no protection against
this other disease, any measured vaccine effectiveness would be
indicative of unmeasured confounding. A bias-indicator study of
oral cholera vaccine in Mozambique evaluated the vaccine’s effec-
tiveness against non-cholera diarrhea, and found an effectiveness
of 35% (95% CI 18% to 65%); however after adjustment for known
confounders the vaccine effectiveness was 0%. This suggests that
while there was confounding of the effectiveness results, it was
not due to unmeasured confounding [37]. A limitation of the bias
indicator study is the assumption that vaccine effects are specific
to the vaccine target, whereas there is increasing evidence that
some vaccines may have non-specific effects that could reduce
the risk for non-targeted infections [51]. Non-infectious illnesses
(e.g. accidents or injuries) could be considered as outcomes for bias
indicators studies. Another type of study to quantify unmeasured
confounding has been dubbed a ‘‘sham exposure” [50] or ‘‘sham
case-control” [52] study. Here vaccine effectiveness of another vac-
cine is measured against the disease of interest. In Kenya, investi-
gators measured the effectiveness of diphtheria-tetanus-pertussis-
Hib-Hepatitis B vaccine against rotavirus disease among children
prior to the expected introduction of the rotavirus vaccine in
2014 and found no protection [52]. Because sham case-control
studies are generally carried out before the introduction of a new
vaccine, they require advance planning and resources. When feasi-
ble, they can be useful for planning case-control studies, for exam-
ple by revealing the least biased control group or identifying
measurable confounders in the population.
4. Implementation and adherence to protocols
The quality of data on enrollment, vaccination status, and
potential confounders depends on writing and implementing clear
protocols and Standard Operating Procedures (SOPs) for study con-
duct. Efforts to recruit cases and controls should be documented
using standardized forms such as screening logs or registers; such
documentation can be used to monitor the adherence to study pro-
cedures and identify lapses as quickly as possible.
Because of potential for selection bias in control enrollment for
vaccine effectiveness case-control studies, it is particularly impor-
tant to standardize, document clearly in logs, and regularly moni-
tor at the field level, the process for enrolling controls [53]. This
should include the number of potential controls screened, number
and timing of attempts made to enroll potentially eligible controls,
the reasons for non-enrollment of potential controls, the frequency
of refusals, and the number and characteristics of the controls who
were not enrolled. Some methods for supervision of field staff
enrolling controls may include GPS tracking of field staff (to mon-
itor their locations and pace of recruitment and enrollment) and
intermittent supervisor monitoring of the homes that were visited.
Any departures from the protocol or SOPs must be reported to
study lead investigators and documented.
5. Analysis
The statistical analysis of a case-control study for the evaluation
of vaccine effectiveness should follow directly from the protocol
and analysis plan, which should define the outcomes to be exam-
ined, as well as the exposures of interest (e.g. complete schedule,
2 or more doses). The ‘‘unadjusted” effectiveness from a case-
control study is calculated as (1 – odds ratio for vaccination) 
100%.
For cases, vaccination status is defined based on the number of
doses received before becoming ill and usually excludes doses
received within the two weeks prior to allow for induction of
immune response. For individually matched controls, a reference
date should be defined in order to examine the control’s vaccina-
tion status before the corresponding case became ill [42]; the ref-
erence date is often based on the case’s date of illness onset, but
may be based upon the date of hospitalization or sample collection.
Doses received more than two weeks (if this is the period used for
the case) before the reference date should be considered in the
analysis. For frequency matched controls, the situation in which
multiple controls are matched to multiple cases, there are different
reference dates (or ages) associated with each of the cases and con-
trols, and the analysis must take account of this. A method for
doing this has been described by Keogh et al. [54].
The odds ratio is usually calculated from a logistic regression
model, using unconditional logistic regression for unmatched or
frequency matched studies, and conditional logistic regression for
matched studies, with strata defined for each matched case-
control set [55]. For simple conditional logistic regression, only
discordant strata (e.g. vaccinated cases with at least one non-
vaccinated control, or non-vaccinated case with at least one vacci-
nated control) contribute to the analysis [55]; thus in settings of
very high or low vaccine coverage, the power of the analyses will
be reduced.
While all efforts should be made in the study design phase to
minimize confounding (e.g. by matching), it is usually necessary
to also control for confounding in the analysis, where potential
confounders are included as independent variables in a regression
model. Because inclusion of multiple covariates can result in loss of
statistical power, it is important to avoid including factors that are
not true confounders. There is no formal statistical test for evaluat-
ing whether to include a potential confounder in the final analysis
[46]. Some researchers approach the inclusion of confounders
based on the past literature and include all potential confounders
in a full model. Others prefer to evaluate potential confounders
based on the data of the current study. A common approach to con-
founder evaluation is to include both vaccination status and single
potential confounders, one at a time, as independent variables in
the logistic regression model. If the OR associated with vaccination
status changes by a predetermined, albeit arbitrary, percent (e.g.
10%) or more after adjusting for the potential confounder, then that
variable is retained in the final multivariable model since it
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appears to impact the VE [41]. Another approach for determining
which variables to include in a multivariable model is the use of
directed acyclic graphs, which are causal diagrams used to identify
a subset of covariates that address confounding while avoiding
introduction of bias [56]. Directed acyclic graphs have been used
for case-control vaccine effectiveness studies of influenza [57,58].
While different strategies for identifying important confounding
variables are acceptable, the method used should be determined
at the stage of developing the analytic plan.
Before deciding on a final model, some investigators prefer to
examine whether the odds ratio (and thereby the VE) differ
between strata of potential confounders (i.e. effect modification).
This may be formally tested using appropriate interaction terms
in the regression models. If such interaction is meaningful and sta-
tistically significant, stratum-specific VEs might be reported [59].
For example, in a study of the 7-valent pneumococcal conjugate
vaccine in the United States, the effectiveness against vaccine-
type and non-vaccine type invasive pneumococcal disease was
presented for healthy children and those with comorbidities, since
this variable was found to have significant interaction with vacci-
nation status [14].
Missing vaccination data present a problem in a vaccine effec-
tiveness case-control study, since those with missing data likely
differ from those with a documented vaccination history in ways
that could bias effectiveness estimates. One approach to handling
missing vaccination histories is to conduct a sensitivity analysis.
The simplest sensitivity analysis assumes those with a missing vac-
cination history are either all unvaccinated or all completely vacci-
nated, providing two estimates of effectiveness under two different
assumptions. A study of the Hib vaccine conducted in the Domini-
can Republic used this approach and found very little impact on
the results, suggesting that the findings of the primary analysis
were not substantially biased by the missing vaccination history
data [60]. Sensitivity analysis could also be conducted to examine
the impact of low (and potentially biased) enrollment of controls
on effectiveness estimates by assuming a range of vaccine coverage
for individuals who were eligible but not enrolled. Methodological
approaches to dealing with missing data have been advancing
rapidly, and although there has been little work in vaccine effec-
tiveness studies evaluating the usefulness of multiple imputation
for missing vaccination histories for enrolled participants (or
non-enrolled participants, as mentioned above), this approach
warrants exploration [61]. Nonetheless, all possible efforts should
be made to obtain as complete information as possible on vaccina-
tion status of cases and controls; no sensitivity analysis or imputa-
tion can fully compensate for data completeness and validity.
6. Reporting study results
The STROBE (STrengthening the Reporting of OBservational
studies in Epidemiology) guidelines for reporting on case-control
studies are an excellent reference for determining the key pieces
of information to record for a vaccine effectiveness study [62].
For case-control vaccine effectiveness studies, it is crucial to pro-
vide a clear and explicit description of the recruitment strategy
for cases and controls, and to carefully document non-enrollment
as well as enrollment. Readers should be given a clear understand-
ing of how many potential cases and controls were screened to
achieve the number of enrolled participants and the primary rea-
sons for non-enrollment (e.g. not eligible, unable to contact,
refused participation). The number of cases and controls with no
documented vaccination history should also be stated in the
results. Relevant differences between included and not included
cases and controls, as well as between those with and without reli-
able vaccination history, should be documented.
In interpreting the study findings, investigators should focus on
the confidence intervals of effectiveness estimates. Although read-
ers or policy makers may be naturally drawn to point estimates,
confidence intervals add crucial information on the precision of
these estimates. Reports of case-control vaccine effectiveness stud-
ies should also include a discussion of the limitations and potential
sources of bias, taking into consideration the inherent limitations
of the study design.
7. Conclusions
The case-control methodology is frequently used to evaluate
the effectiveness of new vaccines, providing important data on
the ‘real-world’ performance of vaccines that guide decisions about
vaccine introduction and sustained use [63,64]. However, the
potential for bias and confounding is high, and can threaten the
validity of the findings. Studies aimed at better understanding bias
in case-control studies, such as a simulation model estimating
potential biases in influenza vaccine effectiveness studies [65],
can advance the field and provide more specific guidance regarding
circumstances in which the case-control approach is likely to yield
reliable results.
High quality vaccination data collected using the methods for
cases and controls is crucial for vaccine effectiveness studies; in
settings where documented vaccination histories are difficult to
obtain, case-control vaccine effectiveness studies are unlikely to
be useful. Variables that confound the association between vacci-
nation and disease should be carefully measured and adjusted for
in the analysis. In reporting the results of a case-control vaccine
effectiveness study, it is important to include information that pro-
vides insight into the degree of possible bias in enrollment and
data collection, such as the number of potential controls screened
or the proportion of cases and controls with documented vaccine
history. Vaccine effectiveness estimates should be presented with
emphasis on the confidence interval rather than the point esti-
mate. In order for case-control studies to accurately guide vaccine
policy decisions, data collection must be thorough and with careful
attention to minimize bias, the analysis performed per the analytic
plan with attention to potential confounding, and the results care-
fully interpreted and presented.
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